Latest market price
17.30
+0.61+3.65%
Earnings
Up 3.7% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -3.33 | Insider Own | 13.51% | Shs Outstand | 186.75M | Perf Week | 10.05% |
| Market Cap | 3.23B | Forward P/E | — | EPS next Y | -3.35 | Insider Trans | -19.27% | Shs Float | 153.33M | Perf Month | 13.82% |
| Enterprise Value | 2.35B | PEG | — | EPS next Q | -0.91 | Short Float | 16.61% | Perf Quarter | -33.38% | ||
| Income | -520.00M | P/S | — | EPS this Y | — | Short Ratio | 8.61 | Perf Half Y | -2.32% | ||
| Sales | 0.00 | P/B | 4.60 | EPS next Y | — | ROA | -52.25% | Short Interest | 25.47M | Perf YTD | -11.55% |
| Book/sh | 3.76 | P/C | 3.60 | EPS next 5Y | — | ROE | -64.30% | 52W High | 27.31 -36.65% | Perf Year | -26.54% |
| Cash/sh | 4.81 | P/FCF | — | EPS past 3/5Y | — | ROIC | -58.28% | 52W Low | 14.00 23.57% | Perf 3Y | 151.82% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 5.52% 5.35% | Perf 5Y | 22.26% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.89 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 12.02 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 54.76 | Recom | 2.21 |
| Dividend Gr. 3/5Y | — | Current Ratio | 12.02 | EPS Q/Q | -11.34% | SMA20 | 8.18% | Beta | 1.22 | Target Price | 35.20 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | — | SMA50 | -5.75% | Rel Volume | 1.04 | Prev Close | 16.69 |
| Employees | 289 | LT Debt/Eq | 0.02 | Earnings | Nov 04 | SMA200 | -10.42% | Avg Volume | 2.78M | Price | 17.30 |
| IPO Date | Sep 17, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -44.23% — | Net Debt/EBITDA | — | Volume | 2,907,337 | Change | 3.65% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-28-26 | Downgrade | Oppenheimer | Outperform → Perform | |
| Sep-30-26 | Reiterated | Stifel Nicolaus | $39 → $37 | |
| Sep-30-26 | Reiterated | Jefferies | Buy | $42 → $50 |
| Sep-30-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $32 |
| Sep-29-26 | Reiterated | Piper Sandler | Overweight | $53 → $47 |
| Sep-09-26 | Reiterated | Robert W. Baird | $30 → $26 | |
| Sep-09-26 | Reiterated | RBC Capital | Outperform | $30 |
| Sep-09-26 | Downgrade | JP Morgan | Neutral → Underweight | |
| Sep-09-26 | Reiterated | Morgan Stanley | Overweight | $45 → $36 |
| Sep-08-26 | Reiterated | Raymond James | Strong Buy | $40 → $37 |
Latest News· Times ET
Oct-28-26
Oct-28-2604:33AM
Oct-22-26
Oct-22-2604:05PM
Oct-09-26
Sep-30-26
Sep-30-2609:30AM
Sep-29-26
Sep-29-2604:05PM
Sep-17-26
Sep-17-2604:05PM
Sep-14-26
Sep-14-2612:21PM
Sep-09-26
Sep-09-2607:45AM
01:21AM
Sep-08-26
Sep-08-2601:40PM
10:30AM
07:51AM
Sep-04-26
Sep-04-2603:23AM
Sep-03-26
Sep-03-2607:30AM
Sep-02-26
Company
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 2 | 2 | 2 | — | — | — | — | — | |
| Gross Profit | -1 | -2 | -2 | -2 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 91 | 70 | 62 | 31 | — | — | — | — | — | |
| Research and Development | 445 | 398 | 281 | 211 | — | — | — | — | — | |
| Other Operating Expense | 1 | -2 | -1 | -2 | — | — | — | — | — | |
| Operating Income | -537 | -468 | -344 | -242 | — | — | — | — | — | |
| Interest Expense | 15 | 6 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 33 | 28 | 26 | 6 | — | — | — | — | — | |
| Net Income Before Taxes | -520 | -446 | -317 | -236 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -520 | -446 | -317 | -236 | — | — | — | — | — | |
| Net Income From Continuing Operations | -520 | -446 | -317 | -236 | — | — | — | — | — | |
| Net Income | -520 | -446 | -317 | -236 | — | — | — | — | — | |
| EPS (Recurring) | -3.33 | -3.47 | -3.37 | -3.95 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.33 | -3.47 | -3.37 | -3.95 | — | — | — | — | — | |
| EPS (Diluted) | -3.33 | -3.47 | -3.37 | -3.95 | — | — | — | — | — | |
| EBITDA | -495 | -438 | -316 | -234 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 165 | 128 | 94 | 60 | — | — | — | — | — | |
| Market Capitalization | 2,855 | 2,504 | 2,215 | 798 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Posner Brian S | Director | Oct 02 '26 | Buy | 16.00 | 2,500 | 40,000 | 27,000 | Oct 06 |
| Cox John | CEO & President | Sep 08 '26 | Sale | 18.88 | 5,658 | 106,823 | 357,507 | Sep 08 |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sep 08 '26 | Sale | 18.88 | 185 | 3,493 | 152,897 | Sep 08 |
| Kerr Douglas | Chief Medical Officer | Sep 08 '26 | Sale | 18.88 | 1,290 | 24,355 | 162,564 | Sep 08 |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sep 04 '26 | Sale | 24.35 | 900 | 21,915 | 153,082 | Sep 08 |
| Kerr Douglas | Chief Medical Officer | Sep 04 '26 | Sale | 24.35 | 3,745 | 91,191 | 163,854 | Sep 08 |
| Rhodes Jason P | Director | Aug 14 '26 | Sale | 25.00 | 2,160,516 | 54,012,900 | 428,946 | Aug 17 |
| Rhodes Jason P | Director | Aug 13 '26 | Sale | 26.20 | 426,412 | 11,171,995 | 751,411 | Aug 17 |
| Friedl-Naderer Johanna | Chief Commercial Officer | Aug 13 '26 | Sale | 26.28 | 226 | 5,939 | 153,982 | Aug 17 |
| Kerr Douglas | Chief Medical Officer | Aug 13 '26 | Sale | 26.28 | 1,556 | 40,892 | 167,599 | Aug 17 |
| Cox John | CEO & President | Aug 13 '26 | Sale | 26.28 | 4,986 | 131,032 | 363,165 | Aug 17 |
| Lucera Erick | Chief Financial Officer | Aug 13 '26 | Sale | 26.28 | 1,797 | 47,225 | 119,766 | Aug 17 |
| Kersten Dirk | Director | Jul 27 '26 | Sale | 25.51 | 261,460 | 6,670,770 | 3,586,796 | Jul 29 |
| Rhodes Jason P | Director | Jul 07 '26 | Sale | 23.26 | 297,211 | 6,913,821 | 2,962 | Jul 08 |
| Rhodes Jason P | Director | Jul 06 '26 | Sale | 22.79 | 480,240 | 10,944,670 | 875,912 | Jul 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.